In a statement, the company says the overall mortality rate for the drug is 12.4/100 patient years, less than half of overall mortality rate of 28.2/100 patient years in people with PDP.
It also says it maintains a close watch on safety reports to ensure that NUPLAZID performs as expected, adding that two studies in Alzheimer’s patients (after FDA approval for PDP) with dementia showed no difference in mortality rates versus placebo.
It also cautions on drawing conclusions from the adverse event data since it does not mean that the medication caused the event.
We think shares are being slammed unfairly here, and think a speculative trade can be considered
Your input is required
Disagree, or have your own opinion? SUBMIT AN ARTICLE TODAY
Feel like commenting? Do you want to join a community of investors and start making money, for free? Then REGISTER now:
We want you to join our community
Benefits of signing up for a FREE membership now:
-No more costly delays in waiting for material
-Dozens of publications per week, including news coverage, earnings commentary, analysis, politics, and more
-Access to special guest contributions, including from WSJ, CNBC, and prolific independent authors
–Ability to comment on articles
–Access to our weekly newsletter
-Publish your own opinion/analysis
Thank you for your readership, and for your loyalty.